Table 5.
Adjusted Model for Prevalence of Receiving Combination Antiretroviral Prophylaxis as Newborn Regimen: Sensitivity Analysis Including ZDV+SD NVP as a Combination Regimen
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Covariate | Prevalence ratioa(95% CI) | p | Prevalence ratio (95% CI) | p |
| Birth year (ref: >2010) | ||||
| 1996–2000 | 0.81 (0.63–1.04) | 0.10 | 0.63 (0.44–0.89) | 0.01 |
| 2001–2005 | 0.81 (0.61–1.06) | 0.12 | 0.73 (0.54–0.98) | 0.04 |
| 2006–2010 | 0.72 (0.56–0.93) | 0.01 | 0.66 (0.51–0.86) | 0.002 |
| Maternal viral loadb (copies/mL) (ref: ≤400 copies/mL) | ||||
| >1000 | 2.02 (1.65–2.47) | <0.001 | 1.96 (1.51–2.54) | <0.001 |
| 401–1000 | 1.61 (1.13–2.29) | 0.01 | 1.58 (1.07–2.33) | 0.02 |
| Maternal CD4 countb (cells/μL) (ref: ≥350 cells/μL) | ||||
| <200 | 1.98 (1.52–2.58) | <0.001 | 1.60 (1.21–2.11) | 0.001 |
| 200–349 | 1.74 (1.39–2.18) | <0.001 | 1.62 (1.29–2.04) | <0.001 |
| Time initiating ARV regimen (ref: 1st or 2nd trimester) | ||||
| No ARV | 2.06 (1.28–3.32) | 0.003 | 1.52 (0.81–2.82) | 0.19 |
| Late ARV (3rd trimester) | 1.05 (0.78–1.42) | 0.74 | 0.94 (0.67–1.32) | 0.73 |
| Cesarean delivery (vs vaginal) | 1.53 (1.25–1.86) | <0.001 | 1.45 (1.17–1.81) | <0.001 |
| Maternal gonorrhea during pregnancy | 1.49 (0.91–2.44) | 0.11 | 1.51 (0.95–2.38) | 0.08 |
| Race/ethnicity (ref: back non-Hispanic) | ||||
| Hispanic | 0.59 (0.47–0.74) | <0.001 | 0.64 (0.50–0.82) | <0.001 |
| White non-Hispanic | 1.16 (0.87–1.56) | 0.32 | 1.20 (0.85–1.68) | 0.30 |
Combination prophylaxis defined as at least two ARV drugs received in the first 8 weeks of life, or ZDV+SD NVP, compared to monotherapy (primarily ZDV).
a
Unadjusted associations are only shown for those predictors retained in the final adjusted multivariable model.
b
Latest measure before or at labor/delivery
ARV, antiretroviral; CI, confidence interval; ZDV, zidovudine; ZDV+SD NVP, Zidovudine plus single-dose nevirapine.